Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

Jorge Cortes, Hagop Kantarjian, Edward D. Ball, John DiPersio, Jonathan E. Kolitz, Hugo F. Fernandez, Mark Goodman, Gautam Borthakur, Maria R. Baer, Meir Wetzler

Research output: Contribution to journalArticle

21 Scopus citations

Fingerprint Dive into the research topics of 'Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences